-$0.52 Earnings Per Share Expected for XOMA Co. (XOMA) This Quarter

Wall Street brokerages predict that XOMA Co. (NASDAQ:XOMA) will post earnings of ($0.52) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for XOMA’s earnings, with estimates ranging from ($0.99) to ($0.15). XOMA reported earnings of ($2.30) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 77.4%. The business is scheduled to report its next earnings results on Tuesday, May 8th.

According to Zacks, analysts expect that XOMA will report full year earnings of ($1.24) per share for the current financial year, with EPS estimates ranging from ($1.80) to ($0.85). For the next financial year, analysts anticipate that the company will post earnings of ($1.09) per share, with EPS estimates ranging from ($1.32) to ($0.65). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that that provide coverage for XOMA.

How to Become a New Pot Stock Millionaire

XOMA (NASDAQ:XOMA) last released its earnings results on Wednesday, March 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.19. XOMA had a negative return on equity of 130.44% and a net margin of 27.49%. The firm had revenue of $5.36 million for the quarter, compared to analyst estimates of $4.12 million.

XOMA has been the topic of several analyst reports. ValuEngine raised XOMA from a “sell” rating to a “hold” rating in a research note on Friday, March 9th. HC Wainwright reissued a “buy” rating and issued a $49.00 target price on shares of XOMA in a research note on Thursday, January 18th. Wedbush reissued a “buy” rating and issued a $33.00 target price on shares of XOMA in a research note on Tuesday, December 19th. Finally, Zacks Investment Research reaffirmed a “hold” rating on shares of XOMA in a research report on Saturday. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $38.33.

NASDAQ:XOMA opened at $20.90 on Friday. XOMA has a 1-year low of $5.86 and a 1-year high of $37.25. The company has a current ratio of 5.96, a quick ratio of 5.96 and a debt-to-equity ratio of 2.52. The stock has a market capitalization of $174.14, a price-to-earnings ratio of 21.33 and a beta of 3.05.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can acquired a new stake in shares of XOMA during the fourth quarter worth about $138,000. Acadian Asset Management LLC acquired a new stake in shares of XOMA during the fourth quarter worth about $152,000. Gotham Asset Management LLC acquired a new stake in shares of XOMA during the fourth quarter worth about $267,000. Wells Fargo & Company MN raised its position in shares of XOMA by 4,288.9% during the fourth quarter. Wells Fargo & Company MN now owns 8,295 shares of the biotechnology company’s stock worth $295,000 after purchasing an additional 8,106 shares during the period. Finally, Alps Advisors Inc. acquired a new stake in shares of XOMA during the fourth quarter worth about $321,000. 38.90% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3342824/0-52-earnings-per-share-expected-for-xoma-co-xoma-this-quarter.html.

XOMA Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Get a free copy of the Zacks research report on XOMA (XOMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Swarm City  Price Tops $1.73 on Exchanges
Swarm City Price Tops $1.73 on Exchanges
ColossusCoinXT 1-Day Trading Volume Reaches $91,527.00
ColossusCoinXT 1-Day Trading Volume Reaches $91,527.00
QuinStreet Inc  Director Sells $2,513,114.92 in Stock
QuinStreet Inc Director Sells $2,513,114.92 in Stock
UnitedHealth Group’s  “Buy” Rating Reaffirmed at Piper Jaffray
UnitedHealth Group’s “Buy” Rating Reaffirmed at Piper Jaffray
Halliburton  PT Raised to $51.00 at Bank of America
Halliburton PT Raised to $51.00 at Bank of America
Insider Selling: Nektar Therapeutics  SVP Sells 13,881 Shares of Stock
Insider Selling: Nektar Therapeutics SVP Sells 13,881 Shares of Stock


Leave a Reply

© 2006-2018 Ticker Report. Google+.